Contact information
Research groups
Altar M. Munis
PhD, BSc (Hons)
Postdoctoral Research Scientist
Funded by the Wellcome Trust, I am working on the development and optimisation of lentiviral gene therapy for lung diseases. In particular, my current project focuses on the treatment of surfactant protein B deficiency, a fatal autosomal recessive genetic disorder, using Sendai virus F/HN pseudotyped vectors.
Prior to joining the Gene Medicine group, I undertook my doctoral studies in gene therapy and immunology at University College London investigating the properties of phylogenetically distinct vesiculovirus glycoproteins that may have advantages over the prototypical glycoprotein from VSV Indiana strain.
Recent publications
-
Genomic diversity of SARS-CoV-2 in Oxford during United Kingdom’s first national lockdown
Journal article
Munis AM. et al, (2021), Scientific Reports, 11
-
Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus.
Journal article
Downes DJ. et al, (2021), Nat Genet, 53, 1606 - 1615
-
RNA-Seq Analysis of the Human Surfactant Air-Liquid Interface Culture Reveals Alveolar Type II Cell-like Transcriptome
Journal article
Munis AM. et al, (2021), Molecular Therapy - Methods & Clinical Development
-
A human surfactant B deficiency air-liquid interface cell culture model suitable for gene therapy applications
Journal article
Munis AM. et al, (2021), Molecular Therapy - Methods and Clinical Development, 20, 237 - 246
-
Genome-wide Integration Site Detection Using Cas9 Enriched Amplification-free Long-range Sequencing
Journal article
HYDE S. et al, (2020), Nucleic Acids Research